Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
BridgeBio Pharma (Nasdaq: BBIO) announced on May 8, 2026 that its compensation committee approved inducement equity grants for 52 new employees totaling 115,007 restricted stock units. One-quarter vests on May 16, 2027, then one‑twelfth of the remainder vests quarterly thereafter, subject to continued employment. Awards were granted under the company’s equity plan adopted November 2019 and amended February 10, 2023 and December 13, 2023, in compliance with Nasdaq Listing Rule 5635(c)(4).
BridgeBio (NASDAQ: BBIO) reported $194.5M total revenue for Q1 2026, including $180.6M of U.S. Attruby net product revenue, and $940.2M in cash, cash equivalents and marketable securities as of March 31, 2026. The Board authorized a $500M share repurchase program.
Pipeline updates: NDA submitted for BBP-418 (LGMD2I/R9); encaleret NDA planned 1H 2026; infigratinib NDA planned Q3 2026. Attruby approvals expanded (Brazil) and new survival and real-world data presented at major meetings.
BridgeBio (Nasdaq: BBIO) announced management will participate in investor fireside chats at three healthcare conferences in May–June 2026: BofA Health Care Conference (May 12, 2:20 pm PDT), Jefferies Global Healthcare Conference (June 4, 11:05 am EDT), and Goldman Sachs Global Healthcare Conference (June 9, 8:00 am EDT).
Live webcasts will be available via the company’s Events and Presentations investor page and replays will remain online for 90 days after each event.
BridgeBio (Nasdaq: BBIO) announced ANVISA approval of BEYONTTRA (acoramidis) to treat wild-type or variant transthyretin amyloidosis cardiomyopathy (ATTR-CM) in adults in Brazil. Approval follows the Phase 3 ATTRibute-CM trial (632 patients) showing a 42% reduction in composite all-cause mortality and recurrent CV hospitalization and a 50% reduction in cumulative CV hospitalizations at Month 30. BEYONTTRA is described as a near-complete (≥90%) TTR stabilizer and already carries approvals in the U.S., EU, UK, Switzerland, and Japan. Commercialization in Brazil is planned with Biopas beginning in H2 2026.
BridgeBio (NASDAQ: BBIO) will present primary Phase 3 CALIBRATE results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) at the 2026 European Congress of Endocrinology (ECE) in Prague.
Presentations include two oral talks (May 12), one poster (P72) and one ePoster (EP260); presenters include Filomena Cetani and Arun Mathew.
BridgeBio (NASDAQ: BBIO) announced presentations of new Phase 3 ATTRibute-CM data for acoramidis at ESC-Heart Failure 2026 in Barcelona on May 9–12, 2026.
Highlights include a late-breaking oral presentation by Bayer on outpatient worsening heart failure, data on NT-proBNP at Month 30, and KCCQ-OS quality-of-life results.
BridgeBio (Nasdaq: BBIO) will report first quarter 2026 financial results and provide commercial and program updates after market close on Thursday, May 7, 2026.
A conference call and live webcast will begin at 4:30 pm ET. A replay will be available on the company website for 30 days.
BridgeBio (Nasdaq: BBIO) launched a national health-education campaign, Don’t Pass On Your Heart Health, to raise awareness of ATTR-CM and encourage earlier diagnosis and care among adults over 55.
The effort features Morgan Freeman and Howard “H” White, highlights findings from the Phase 3 ATTRibute-CM study showing treatment benefits with Attruby, and provides resources at Attruby.com.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved April 18, 2026, for 33 new employees totaling 67,247 restricted stock units.
Vesting: 25% vests on May 16, 2027, then one‑twelfth of the remainder quarterly thereafter, subject to continued employment. Awards were granted under the company’s plan adopted November 2019 and amended February 10, 2023 and December 13, 2023.
BridgeBio (Nasdaq: BBIO) presented long-term data showing acoramidis provides sustained benefit through Month 54 in ATTR-CM. Continuous treatment reduced all-cause mortality by 44.7% and cardiovascular mortality by 49.3% (both p<0.0001) versus placebo-to-acoramidis.
Acoramidis mitigated NT-proBNP rise, stabilized KCCQ-OS heart-failure scores, was well tolerated long term, and is approved in the U.S., EU, Japan, Switzerland and the UK.